- Previous close
164.47 - Open
164.89 - Bid 164.70 x 1000
- Ask 165.12 x 1000
- Day's range
163.93 - 165.29 - 52-week range
143.13 - 168.85 - Volume
4,188,043 - Avg. Volume
6,369,750 - Market cap (intra-day)
397.483B - Beta (5Y monthly) 0.52
- PE ratio (TTM)
27.34 - EPS (TTM)
6.04 - Earnings date 15 Oct 2024
- Forward dividend & yield 4.96 (3.00%)
- Ex-dividend date 26 Nov 2024
- 1y target est
174.44
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
www.jnj.com131,900
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Drug Manufacturers - General
Industry
Recent news: JNJ
View more
Related videos: JNJ
Performance overview: JNJ
Trailing total returns as of 18/10/2024, which may include dividends or other distributions. Benchmark is
.YTD return
1-year return
3-year return
5-year return
Compare to: JNJ
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: JNJ
View moreValuation measures
Market cap
397.48B
Enterprise value
413.50B
Trailing P/E
27.29
Forward P/E
15.43
PEG ratio (5-yr expected)
0.98
Price/sales (ttm)
4.58
Price/book (mrq)
5.56
Enterprise value/revenue
4.72
Enterprise value/EBITDA
18.31
Financial highlights
Profitability and income statement
Profit margin
16.74%
Return on assets (ttm)
--
Return on equity (ttm)
--
Revenue (ttm)
87.7B
Net income avi to common (ttm)
14.77B
Diluted EPS (ttm)
6.04
Balance sheet and cash flow
Total cash (mrq)
25.48B
Total debt/equity (mrq)
58.00%
Levered free cash flow (ttm)
--